Humana explicitly excludes weight loss as a covered indication for GLP-1 medicationsthis isn't a prior authorization denial, it's a plan exclusion that blocks claims at the pharmacy level
As a result of the court ruling, this marks the end of the Food and Drug Administrations (FDA) enforcement discretion as follows: Small-scale compounders (i.e., 503A facilities), licensed by individual states and physician compounding, must stop producing compounded tirzepatide immediately
2 Check for signs and symptoms
Until next time, Andy De Santis RD MPH
The semaglutide component is the same active ingredient
Sn phm c sn xut ti M trong c s t chun quc t cGMP, hon ton khng cha cht kt dnh, gluten, sa, trng, la m, u nnh, cht ph gia v cht bo qun